Drug Trial Radar · NCT07697443
Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Sep 12, 2026
Primary completion
Aug 2029
Study completion Aug 2030
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study includes Phase I dose escalation and expansion and Phase II combination therapy. It uses a multicenter, open-label, non-randomized design to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3126 in breast cancer. Phase I dose escalation uses a Rolling 6 design after accelerated titration at the first dose, with dose decisions reviewed by the Safety Review Committee. Dose expansion includes two cohorts of approximately 20-60 participants each. The study also explores relationships between drug exposure and efficacy/safety, including concentration-QTc assessment using Holter electrocardiograms.
Conditions
- Breast Cancer
Interventions
TQB3126Drug
TQB3126 is a targeted protein degrader.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT)Time frame: From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.
- Maximum Tolerated Dose (MTD)Time frame: From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.
- Recommended Phase II Dose (RP2D)Time frame: Observation is expected to continue through Cycle 6 Day 28 throughout the study, around 6 months.
- Adverse Events (AEs)Time frame: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
- Serious Adverse Events (SAEs)Time frame: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
- Abnormal Incidence of Laboratory Test IndicatorsTime frame: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
- Objective Response Rate (ORR)Time frame: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
- Maximum Applicable Dose (MAD)Time frame: From the first dose of TQB3126 through completion of the Phase I dose-escalation assessment.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Meizhou People's Hospital
Meizhou, Guangdong, China · Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.